Epidermal Growth Factor Receptor (EGFR) signaling represents an emerging therapeutic target for Parkinson's disease, with growing evidence supporting its neuroprotective effects on dopaminergic neurons. Unlike cancer therapy where EGFR inhibition is the goal, Parkinson's disease requires EGFR activation to promote neuronal survival, mitochondrial protection, and autophagy. The EGFR family (ErbB1/EGFR, ErbB2, ErbB3, ErbB4) plays critical roles in neural development, maintenance, and repair in the adult brain[1].
This page catalogs companies developing EGFR-targeted therapies for Parkinson's disease, including:
The field faces unique challenges, primarily the blood-brain barrier penetration required for CNS delivery and the need to balance neuroprotective effects against potential oncogenic risks[2].
The EGFR therapy field for neurodegenerative disease is in early stages compared to oncology applications:
Unlike the mature LRRK2 inhibitor pipeline for PD, EGFR-targeted approaches remain largely in discovery and preclinical stages, though several companies have active programs targeting ErbB signaling for neurological disorders.
| Attribute | Value |
|---|---|
| Headquarters | Tokyo, Japan |
| Ticker | FUJI (TYO) / FJLIY (OTC) |
| Founded | 2006 (from merger) |
| Focus | Regenerative medicine, growth factor therapeutics |
Fujifilm, through its subsidiary Fujifilm Cellular Dynamics (formerly iPSC portal), has developed expertise in growth factor biology and iPSC-derived dopaminergic neurons. The company has explored EGF and related growth factors for neural cell culture and therapy development.
Technology Platform:
EGFR Program:
| Attribute | Value |
|---|---|
| Headquarters | Osaka, Japan |
| Ticker | 4506 (TYO) |
| Founded | 2005 (from merger) |
| Focus | CNS therapeutics, regenerative medicine |
Sumitomo Pharma has a long history in neuroscience research and has investigated growth factor therapies for neurodegenerative diseases. The company has explored EGF and TGF-α delivery approaches for PD.
Technology Platform:
EGFR Program:
| Attribute | Value |
|---|---|
| Headquarters | Tokyo, Japan |
| Ticker | TAK (NYSE) |
| Founded | 1781 |
| Focus | Pharmaceutical research and development |
Takeda has one of the largest neuroscience portfolios in the pharmaceutical industry and has shown interest in neurotrophic factor approaches for neurodegenerative diseases. The company has explored ErbB signaling modulation.
Technology Platform:
EGFR Program:
| Attribute | Value |
|---|---|
| Headquarters | Boston, Massachusetts |
| Ticker | CERE (NASDAQ) |
| Founded | 2018 |
| Focus | CNS therapeutics, receptor modulation |
Cerevel Therapeutics, a subsidiary of Pfizer, is developing novel small molecule therapeutics for neurological and psychiatric disorders. The company has explored ErbB family modulators for CNS applications.
Technology Platform:
EGFR Program:
| Attribute | Value |
|---|---|
| Headquarters | San Diego, California |
| Ticker | NBIX (NASDAQ) |
| Founded | 1992 |
| Focus: CNS and pipeline disorders |
Neurocrine Biosciences has developed therapies for neurological and psychiatric disorders. The company has explored GPCR and growth factor signaling pathways relevant to neurodegenerative diseases.
Technology Platform:
EGFR Program:
| Attribute | Value |
|---|---|
| Headquarters | Cambridge, Massachusetts |
| Founded | 2021 |
| Focus | Growth factor therapeutics for neurodegeneration |
Neuronex is an academic spinout focused on developing next-generation growth factor therapeutics for neurodegenerative diseases. The company was founded based on research from major US universities on EGF family ligands.
Technology Platform:
EGFR Program:
| Attribute | Value |
|---|---|
| Headquarters | Seattle, Washington |
| Ticker | KLDO (NASDAQ) |
| Founded | 2014 |
| Focus | neurotrophic factor therapies |
Athira Pharma, formerly Alkahest, focuses on neurotrophic factor therapies for neurodegenerative diseases. While primarily focused on VEGF and other growth factors, the company has explored the broader EGF superfamily.
Technology Platform:
EGFR Program:
| Attribute | Value |
|---|---|
| Headquarters | New York, New York |
| Ticker | BMS (NYSE) |
| Founded | 1989 |
| Focus | Pharmaceutical research and development |
BMS has extensive experience with EGFR-targeted therapeutics in oncology. The company has explored whether certain EGFR modulators could be repurposed for neuroprotection.
Technology Platform:
EGFR Program:
| Attribute | Value |
|---|---|
| Headquarters | Indianapolis, Indiana |
| Ticker: LLY (NYSE) | |
| Founded | 1876 |
| Focus | Pharmaceutical research and development |
Lilly has a long history in growth factor research and has investigated ErbB signaling in various contexts. The company has explored growth factor therapies for neurological disorders.
Technology Platform:
EGFR Program:
| Attribute | Value |
|---|---|
| Headquarters | Tokyo, Japan |
| Ticker | 4151 (TYO) |
| Founded | 2008 (as Kyowa Hakko Kirin) |
| Focus | Specialty pharmaceuticals |
Kyowa Kirin has developed expertise in growth factors through their erythropoietin (EPO) and G-CSF programs. The company has explored related growth factors for CNS applications.
Technology Platform:
EGFR Program:
| Attribute | Value |
|---|---|
| Headquarters | Matsumoto, Japan |
| Ticker | 4547 (TYO) |
| Founded | 1946 |
| Focus | Pharmaceutical research |
Kissei Pharmaceutical has focused on CNS disorders and has investigated growth factor signaling for neuroprotection.
Technology Platform:
EGFR Program:
| Company | Approach | Stage | Focus |
|---|---|---|---|
| Fujifilm | Growth factor therapy | Research | EGF for neural applications |
| Sumitomo Pharma | Ligand derivatives | Discovery | BBB-penetrant EGF |
| Cerevel Therapeutics | Small molecule modulators | Discovery | ErbB positive modulators |
| Neuronex | Engineered EGF variants | Preclinical | BBB-penetrant EGF analog |
| BMS | Repurposed EGFR modulators | Research | Neuroprotective applications |
| Athira Pharma | Growth factor therapy | Research | EGF family ligands |
| Challenge | Impact | Current Approaches |
|---|---|---|
| BBB penetration | EGF does not cross BBB | Engineered fragments, small molecules |
| Receptor specificity | Systemic EGFR effects cause toxicity | Cell-specific targeting, selective ligands |
| Oncogenic risk | Chronic EGFR activation concerns | Intermittent dosing, brain-specific delivery |
| Therapeutic window | Narrow dose range | Biomarker-guided dosing |
The PD EGFR therapy market presents several opportunities: